从病理和治疗角度,肺癌大致可以分为非小细胞肺癌(non small cell lung cancer,NSCLC)和小细胞肺癌(small cell lung cancer,SCLC)两大类,其中非小细胞肺癌约占80%～85%,包括腺癌、鳞癌等组织学亚型,其余为小细胞肺癌。腺癌的比例最高,占NSCLC的50%。在非小细胞肺癌中,约50%-70%的患者带有EGFR、KRAS突变或ALK...
non-small cell lung cancerscreeningtargeted therapyimmunotherapyepidermal growth factor receptor(EGFR)mutationprogrammed cell death protein 1(PD-1)programmed deathligand 1(PD-L1)clinical trialsclinical guidelinesIn China,lung cancer is a primary cancer type with high incidence and mortality.Risk factors fo...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose...
3、吸烟者和非吸烟者体内各有一套基因突变,非吸烟者(EGFR 突变、ROS1 和ALK 融合) 和 吸烟者(KRAS, TP53, BRAF,JAK2,JAK3 突变和错配修复基因突变)。 4、DNA错配修复基因和染色质相关基因突变及融合基因可能会解决当前治疗的瓶颈。 5、肿瘤发展是一个动态过程,针对亚克隆突变的靶点治疗可能会改善癌症病人的...
Cancer Treatment ReviewsJean-Charles, SoriaTony S., MokFederico, CappuzzoPasi A., Jänne. (2012) EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews 38 , 416-430 /Soria JC, Mok TS, Cappuzzo F, et al. EGFR-mutated ...
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of adv
Key “driver” mutations have been discovered in specific subgroups of non-small-cell lung cancer (NSCLC) patients. Activating mutations in the form of deletions in exon 19 (del 19) or the missense mutation L858R in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) pred...
Impact of EGFR mutation analysis in non-small cell lung cancer. The discovery of mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) accelera... H Yamamoto,S Toyooka,T Mitsudomi - 《Lung Cancer》 被引量: 0发表...
et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004). Article CAS PubMed Google Scholar Paez, J. G. et al. EGFR mutations in lung cancer: correlation with ...